Organization
Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA
1 abstract
Abstract
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.Org: Vanderbilt University Medical Center, University Hospital of Salamanca, Helen Diller Family Comprehensive Cancer Center, Princess Margaret Cancer Centre, Levine Cancer Institute/Atrium Health,